Medical Device Consumables Industry News – July 2026

In July 2026, the cardiovascular interventional consumables sector experienced multiple profound adjustments. From the nationwide implementation of the second round of successive centralized procurement for coronary stents, to the full execution of provincial alliance procurements for pacemakers and peripheral interventional microcatheters, and from multiple innovative device approvals to accelerated international M&A – this month represents a critical window of both challenges and opportunities for companies specializing in cardiovascular intervention and Vascular Access products.

I. Second Round of Successive Centralized Procurement for Coronary Stents Implemented Nationwide

The second round of the national organized centralized volume‑based procurement (CVBP) for coronary stents was fully implemented across the country in July.

Provincial roll‑outs: Jiangsu Province implemented the results effective July 31, with the procurement period extending to June 30, 2029; Fujian Province will implement on August 10; Beijing will implement from August 1, covering five categories including coronary stents, pacemakers, and interventional microcatheters; Hainan will implement from August 10; Hebei initiated tripartite agreement signing on July 28.

Significant demand growth: The annual procurement demand volume for this round reached 2.73 million units, representing a 1.5‑fold increase compared with the initial procurement of 1.07 million units. All 14 originally selected products were renewed, with Medtronic, Abbott, and Boston Scientific competing alongside MicroPort, Lepu, and JW Medical Systems. Newly added selected products include Medtronic's Resolute Onyx. As of April 2026, centrally procured stents accounted for over 90% of all cardiac stent usage.

II. Provincial Alliance Procurements for Pacemakers and Peripheral Interventional Microcatheters Take Effect

Effective July 1, the provincial alliance procurement results for pacemakers (27 provinces, led by Zhejiang Province) and peripheral interventional microcatheters (29 provinces, led by Zhejiang) were officially implemented, with a procurement period of 3 years.

Pacemakers remain dominated by multinationals including Medtronic, Abbott, Biotronik, and Boston Scientific, but domestic players such as Chuangling Heart Rhythm and Lepu have begun to gain market access through the procurement. For peripheral interventional microcatheters, a total of 78 manufacturers were selected. While Covidien, Stryker, Johnson & Johnson, and Terumo still lead in demand volume, domestic brands hold a clear advantage in the number of selected products.

China's pacemaker implant volume increased from 110,130 cases in 2022 to 147,748 cases in 2024, presenting a developmental window for domestic brands.

III. Multiple Provinces Intensively Implement Cardiovascular Interventional Consumables Procurements

Effective August 1, the selected results from 7 provincial alliances were centrally implemented, including: 4 categories led by Henan (coronary interventional balloons, general intervention, neurosurgery, hemodialysis); structural heart disease occluders led by Fujian; pacemakers led by Zhejiang; 5 categories including sutures and syringes led by Liaoning; and hemostatic materials and intraVenous Catheters from the Beijing‑Tianjin‑Hebei "3+N" alliance.

Effective July 20, pacemakers (27 provinces) and peripheral interventional microcatheters (29 provinces) were officially implemented, covering 11,590 selected products.

IV. Domestic Innovative Device Approvals

· Transcatheter Tricuspid Clip System: Approved on July 21 for Hangzhou Duanyou Medical, indicated for tricuspid edge‑to‑edge repair.

· Interventional Left Ventricular Assist Device: Approved for Fengkaili Medical, indicated for high‑risk PCI procedures.

· Intravascular Ultrasound (IVUS) Diagnostic Device and Catheter: Two products approved – one from Shenzhen Haoying Medical, and one from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences.

V. International Updates: FDA Approvals and Global Launches

Johnson & Johnson Dual‑Energy Cardiac Ablation Catheter Receives FDA Approval

On July 8, Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform. The platform allows electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single catheter. The technology received CE Mark approximately 18 months prior, with first U.S. commercial procedures expected to commence in summer 2026. Previously, physicians needed separate catheters and generators for RF and PF energy delivery, increasing procedure time, complexity, and cost.

Johnson & Johnson Launches Next‑Generation Shockwave C2 Aero Coronary IVL Catheter

This month, Johnson & Johnson launched its next‑generation coronary intravascular lithotripsy (IVL) catheter featuring enhanced shaft flexibility, tapered tip, and hydrophilic coating to improve trackability and crossing performance in severely calcified and tortuous anatomies. It is now available in the U.S. and Japan, with European and Canadian launches planned in the coming months. Approximately 315 million people worldwide are affected by coronary artery disease.

ElectroWire Medical LightningWire Transseptal Puncture System Receives FDA Clearance

On July 21, ElectroWire Medical received FDA 510(k) clearance for its LightningWire Transseptal Puncture System. The system combines an electrosurgical guidewire with a dedicated activation cable, suitable for procedures including atrial fibrillation catheter ablation, left atrial appendage closure, and transcatheter mitral valve repair/replacement. This marks an evolution of guidewires from simple access tools to multifunctional devices capable of energy delivery.

Sailun Medical's Non‑Compliant Balloon Dilatation Catheter Receives Colombian Registration

On July 10, Sailun Medical announced that its NC ROCKSTAR™ Non‑Compliant Balloon Dilatation Catheter received registration from Colombia's INVIMA. It is indicated for balloon dilatation of stenotic lesions in native coronary arteries or bypass grafts, and for post‑dilatation of balloon‑expandable stents.

VI. International M&A and Collaborations

Stereotaxis Completes Acquisition of Robocath

On July 9, Stereotaxis announced the completion of its acquisition of Robocath for approximately $20 million in cash and common stock. Robocath specializes in robotics for interventional cardiology and neurointervention. Stereotaxis' robotic platforms have treated over 150,000 patients globally.

Venus Medtech Completes Enrollment in PREVAILS Trial for TAVR Device

On July 23, Venus Medtech announced completion of patient enrollment in the PREVAILS pivotal trial for its Venus‑PowerX transcatheter aortic valve replacement (TAVR) system. The device is described as the world's first self‑expanding dry‑valve TAVR device capable of full retrieval after 100% deployment. The trial data will support simultaneous registration submissions to China's NMPA and for CE Mark under the EU MDR 2017/745.

VII. International Product Recalls

Multiple cardiovascular intervention‑related product recalls were recorded by the FDA this month:

· Abiomed recommended removal of its 14Fr Low Profile Introducer Kits due to higher‑than‑expected thrombosis complaint rates during extended use, with 3 serious injuries reported.

· Boston Scientific recommended removal of specific lots of its ENROUTE Transcarotid Neuroprotection System due to reports of arterial sheath tip separation, with 1 serious injury reported.

· Medtronic's Harmony Delivery Catheter System was classified as a Class I recall (the most severe type) by the FDA.

VIII. Global Market Size

The global interventional cardiology devices market is projected to grow from $31.12 billion** in 2026 to **$42.39 billion by 2031, at a CAGR of 6.4%. The global cardiac rhythm management devices market was valued at approximately $14.6 billion** in 2025 and is expected to reach **$21.0 billion by 2032, at a CAGR of 5.4%.

Boston Scientific reported Q2 cardiovascular net sales of $3.624 billion, an 8.3% year‑over‑year increase, with organic growth in interventional cardiology and vascular therapy reaching 12.1%.

Key Monthly Highlights

· Coronary Stent Renewal (Domestic)：Nationwide implementation, procurement extended to 2029, demand volume 2.73 million units

· Pacemaker/Microcatheter Procurements (Domestic)：27‑province + 29‑province alliances implemented; domestic pacemakers gaining traction; domestic brands lead in microcatheter selection count

· Structural Heart Occluders (Domestic)：Multiple provinces implementing in July–August

· FDA Approval (International)：J&J dual‑energy cardiac ablation catheter approved, ushering in dual‑energy era for electrophysiology

· New Product Launch (International)：J&J Shockwave C2 Aero IVL catheter launched in U.S. and Japan

· FDA Clearance (International)：ElectroWire LightningWire transseptal puncture system cleared; guidewire evolves into electrosurgical tool

· International M&A：Stereotaxis completes $20M acquisition of Robocath

· Domestic Export：Sailun Medical balloon catheter receives Colombian registration

· Clinical Trial：Venus Medtech completes PREVAILS enrollment for Venus‑PowerX

· Product Recalls (International)：Multiple high‑value consumable recalls from Abiomed, Boston Scientific, Medtronic

· Global Market：Interventional cardiology devices market reaches $31.12B in 2026

Disclaimer: This article is for medical popularization, purposes only and does not constitute professional medical advice. Please always follow the diagnosis and treatment plans provided by your treating physician.